OOIR: Observatory of International Research

Papers

(The H4-Index of Biochimica et Biophysica Acta-Reviews on Cancer is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids	427
Unlocking the power of innate lymphoid cell plasticity in the tumor microenvironment: A revolutionary pathway for cancer immunotherapy	256
Spatiotemporal dynamics of the pre-metastatic niche: remodeling of lung microenvironment before breast cancer metastasis and targeted intervention strategies	173
Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives	155
Nutrition and dietary restrictions in cancer prevention	153
Emerging advantages of nano delivery systems in enhancing CAR-T/CRISPR-Cas9 mediated cancer therapeutics	100
Current progression of progesterone receptor and androgen receptor in endometrial cancer	100
Role of N7-methylguanosine in gastrointestinal tumors: Molecular mechanisms and therapeutic targets	92
Targeting ferroptosis with flavonoids for cancer therapy: Mechanisms and opportunities	91
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles	91
Advances in epigenetic modifications and cervical cancer research	89
The role of protein glycosylation in colorectal cancer: From molecular pathways to clinical applications	87
VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis	86
The bridging role of neutrophils in the progression of inflammation-induced colorectal cancer	80
Uveal melanoma modeling in mice and zebrafish	80
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective	73
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer	72
ESR1 activating mutations: From structure to clinical application	72
In what area of biology has a “new” type of cell death been discovered?	70
Fascin-1 in primary liver cancers, perspectives for targeted therapy	68
Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications	66
Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights	64
Dual perspective on autophagy in glioma: Detangling the dichotomous mechanisms of signaling pathways for therapeutic insights	62
Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer	61
Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance	59

Detection methods for mitochondrial DNA heteroplasmy and their potential single-cell applications in cancer	59
Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope	58
Mitochondrial metabolism in laryngeal cancer: therapeutic mechanisms and prospects	58
CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting	54
Yin yang 1: a potential regulator of immune related diseases and cancer immunity	53
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature	52
Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells	52
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges	51
Biomarkers in high grade serous ovarian cancer	49
S100A8 and S100A9 in Cancer	48
Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans	47
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance	47
Advances and prospects of mRNA vaccines in cancer immunotherapy	47
Targeting lipid metabolism in cancer metastasis	47
Decoding the role of FOXP3 in esophageal cancer: Underlying mechanisms and therapeutic implications	46
Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy	43
Emerging perspectives on metabolic reprogramming in the microenvironment of ovarian cancer metastasis	43
Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors	43
The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches	43
Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression	43